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In recent years, tropospheric ozone has been
a primary regulatory focus of the U.S.
Environmental Protection Agency (U.S.
EPA). A revised National Ambient Air
Quality Standard of 0.08 ppm for 8-hr aver-
age concentrations was ﬁnalized in 1997 (1),
based in part on evidence of physiologic
changes and health effects below the previ-
ous primary ozone standard (0.12 ppm, 1-hr
average). 
Although substantial evidence exists on
the molecular and physiologic impacts of
ozone exposure (2), the evidence needed to
quantify the beneﬁts of reducing ozone con-
centrations (for use in beneﬁt–cost analyses)
is surprisingly limited. A beneﬁt–cost analy-
sis of concentration reductions (leaving
aside atmospheric dispersion modeling of
ozone precursors) would need to incorpo-
rate, with a reasonable degree of certainty,
the relationship between ambient concen-
trations and personal exposures; representa-
tive concentration–response functions for
health outcomes for which causality can be
reasonably inferred; and the economic valu-
ations of these health outcomes.
For all three of these categories, signifi-
cant uncertainty exists. Although personal
exposures to ozone could be inﬂuenced by air
conditioning and time spent indoors, possi-
ble geographic differences in concentration–
response functions were not addressed in the
prospective beneﬁt–cost analysis of the Clean
Air Act (CAABCA) (3) or the Regulatory
Impact Analysis (RIA) of the Tier 2 motor
vehicle standards (4). In these studies, ozone
benefits were based largely on a limited
number of studies of selected morbidity
outcomes, and ozone effects on mortality
were considered only in a sensitivity analy-
sis. Economic valuation of premature death
was based largely on studies of populations
that arguably were not representative of
those at risk from air pollution, and many
morbidity valuations were based on limited
studies or on only the direct economic costs
of illness. 
This is not to say that the CAABCA and
the Tier 2 RIA did not represent a good
understanding of the literature on ozone
mitigation benefits; rather, these analyses
demonstrate the relative lack of emphasis on
ozone research relevant to the questions
asked by benefit–cost analysis. A survey of
the literature finds numerous recent meta-
analyses (either qualitative or quantitative)
of the particulate matter (PM) time-series
literature (5–11) but few similar assessments
for ozone (12). Given a limited number of
primary studies and fewer critical assess-
ments of these studies, there is a need for
careful consideration of all elements of
ozone benefit–cost analyses, to ensure that
benefits of ozone reduction are not signifi-
cantly underestimated or overestimated and
to determine areas for future research.
Within this article, our approach is to
focus on elements that would help us interpret
a relatively limited body of literature.
Because one of the overarching questions in
evaluating health effects is determining
causality, we construct our health effects
arguments in light of some of Hill’s causal
criteria (13). We focus primarily on biologic
plausibility, coherence, and strength/consis-
tency of effect. 
Clearly, the U.S. EPA criteria document
and other similar publications cover these
issues (as well as monetary valuation issues)
extensively, and it is not our intent to sum-
marize even approximately the full body of
ozone literature. Rather, our goal is to inter-
pret a limited number of studies that have
provided the primary bases for past ozone
damage estimations. Thus, we do not discuss
some health outcomes (such as eye irritation
or emergency room visits for asthma) that
are commonly associated with ozone but
that were not signiﬁcant contributors to ben-
efits in past analyses (3,4). In addition, we
acknowledge that our analysis represents a
preliminary look at these issues, based on
our subjective judgments. We aim to raise
questions related to uncertainty and the
interpretation of the literature, but a broader
evaluation by experts in the relevant fields
might yield different estimates and charac-
terizations of uncertainty. 
Within this article, we draw conclusions
regarding the interpretation of the current
literature on health effects and monetary
valuation, presenting our best estimates and
estimates of uncertainty. We provide a
hypothetical case study in Houston, Texas,
to demonstrate one approach for applying
past studies to different geographic loca-
tions. We conclude by discussing future
research directions and the appropriate
scope and framing of ozone benefit–cost
analyses. 
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In this paper we examine scientiﬁc evidence and related uncertainties in two steps of beneﬁt–cost
analyses of ozone reduction: estimating the health improvements attributable to reductions in
ozone and determining the appropriate monetary values of these improvements. Although sub-
stantial evidence exists on molecular and physiologic impacts, the evidence needed to establish
concentration–response functions is somewhat limited. Furthermore, because exposure to ozone
depends on factors such as air conditioning use, past epidemiologic studies may not be directly
applicable in unstudied settings. To evaluate the evidence likely to contribute signiﬁcantly to ben-
eﬁts, we focus on four health outcomes: premature mortality, chronic asthma, respiratory hospital
admissions, and minor restricted activity days. We determine concentration–response functions
for these health outcomes for a hypothetical case study in Houston, Texas, using probabilistic
weighting reﬂecting our judgment of the strength of the evidence and the possibility of confound-
ing. We make a similar presentation for valuation, where uncertainty is due primarily to the lack of
willingness-to-pay data for the population affected by ozone. We estimate that the annual mone-
tary value of health beneﬁts from reducing ozone concentrations in Houston is approximately $10
per person per microgram per cubic meter (24-hr average) reduced (95% confidence interval,
$0.70–$40). The central estimate exceeds past estimates by approximately a factor of ﬁve, driven
by the inclusion of mortality. We discuss the implications of our ﬁndings for future analyses and
determine areas of research that might help reduce the uncertainties in benefit estimation. Key
words: beneﬁt–cost analysis, epidemiology, exposure assessment, monetary valuation, ozone, pre-
mature mortality. Environ Health Perspect 109:1215–1226 (2001). [Online 24 November 2001]
http://ehpnet1.niehs.nih.gov/docs/2001/109p1215-1226levy/abstract.htmlRelevant Background
Information
Biologic mechanisms. We brieﬂy discuss the
mechanisms of action for ozone in this sec-
tion to help determine whether health effects
derived from epidemiologic investigations
are biologically plausible. We focus on
review articles considering the molecular
mechanisms of action (14) and physiologic
effects in the mammalian lung (15). 
Ozone is an oxidant gas with three oxy-
gen atoms in the molecule. It is poorly water
soluble, so it does not easily diffuse into tis-
sues, but merely reacts with molecules at the
air–ﬂuid boundary. Ozone also reacts easily
and rapidly with molecules that contain
reactive groups, such as antioxidants or
polyunsaturated fatty acids. There is fairly
good agreement that ozone reactions with
carbon double bonds in the lung lining
ﬂuid’s polyunsaturated fatty acids represent
the primary molecular mechanism for
adverse physiologic effects. In pathologic
conditions such as chronic obstructive pul-
monary disease (COPD) or asthma, the
thickness of the lung lining fluid may be
reduced, and this may have some effect on
the sensitivity to ozone among individuals
with pre-existing respiratory disease (14).
The molecular effects of ozone are medi-
ated somewhat by antioxidants in the lung
lining ﬂuid, which contains large amounts of
urate, ascorbate, and reduced glutathione.
This raises the possibility that there may be a
threshold below which ozone would have
few or no adverse effects, although the vari-
ability in individual sensitivities and antioxi-
dant levels may imply that this putative
threshold would not be seen at the popula-
tion level. Interestingly, there are reports of
compromised antioxidant status in asthmat-
ics, which could sensitize the lung to further
ozone exposures (14,16). 
Ozone causes several changes in the air-
way epithelium. These include necrosis of
ciliated cells and type I pneumocytes, decili-
ation, and degranulation of secretory cells.
Also, tight junctions between epithelial cells
are damaged, and this increases the perme-
ability of the epithelium enabling outcomes
such as protein leakage from the epithelium
to the lung lining ﬂuid and vice versa (14).
Along with an understanding of molecu-
lar mechanisms, there is a reasonable body of
literature describing the physiologic effects of
ozone. Numerous studies have detailed the
fact that ozone exposure leads to short-term
decreases in lung function (12,14,17–19),
apparently caused by a decrease in inspiratory
capacity secondary to sensitization of
bronchial C-fibers (20,21). Inflammatory
mechanisms seem to also be involved, as
ibuprofen and indomethacin have been
shown to reduce the ozone effect (22,23). 
There is also evidence of increased air-
way resistance caused by small airway nar-
rowing, through mechanisms such as
increased smooth muscle tone, edema, local-
ized inflammation, and mucus hypersecre-
tion (14). This may involve ozone effects on
the parasympathetic nervous system. In
addition, ozone can increase reactivity to
nonspecific bronchoconstrictors (24,25),
which may (through inflammatory mecha-
nisms) aggravate symptoms in individuals
who already react to allergens or have
obstructive diseases. 
One key question for interpretation of
epidemiologic ﬁndings is whether long-term
exposure to ozone can lead to chronic health
effects. Evidence from animal and human
exposure studies shows that long-term expo-
sure could produce sustained decrements in
lung function, particularly in small airway
measures (such as forced expiratory flow,
which would be abnormal for individuals
with COPD or asthma) (15). Studies of
chronic ozone exposures (≥ 150 ppb) in
monkeys and rats found thickening of the
epithelium and interstitium of bronchioles
(26,27). The respiratory epithelium was
replaced by bronchial epithelium in the cen-
tral acinar region in rats after long-term
ozone exposure (28). In addition, increased
collagen or ﬁbroblast proliferation has been
observed, suggesting a fibrotic process
(29,30). There is also evidence from animal
studies that exposure to ozone at an early age
can lead to persistent developmental changes
(15), including changes in tracheal mucocil-
iar apparatus (31) and lesions in respiratory
bronchioles (32). Thus, chronic exposure to
ozone appears to cause bronchiolitis with
remodeling of the bronchiolar epithelium
leading to decreased diffusion capacity,
fibrosis leading to reduced lung elasticity,
and proliferation of type II pneumocytes.
These changes have also been found in
autopsied human lungs after long-term
ozone exposure (14,33).
In conclusion, there are well-documented
mechanisms for acute respiratory effects and
limited evidence for chronic respiratory
effects related to ozone exposure. Because the
primary oxidative reactions of ozone seem to
be related to universal properties of the mam-
malian respiratory tract, the animal-to-
human extrapolations would be expected to
have less uncertainty for ozone than for many
other chemicals. However, animals are gener-
ally exposed to concentrations well above
ambient levels, making deﬁnitive conclusions
about effects at ambient levels difficult.
Nevertheless, there appears to be sufficient
evidence for the biologic plausibility of respi-
ratory-related morbidity and mortality. 
Exposure patterns. For benefit–cost
analysis, we are interested in two dimensions
of ozone exposure. First, to evaluate whether
epidemiologic associations can be inter-
preted as causal relationships, we must deter-
mine the general relationship between
ambient concentrations and personal expo-
sures. Second, to extrapolate the epidemio-
logic results to unstudied regions, we must
understand whether there are systematic dif-
ferences in this relationship by location. 
Individuals in developed countries gener-
ally spend most of their time indoors (34),
implying that we need to understand the
relationship between outdoor and indoor
concentrations to evaluate personal expo-
sures. In addition, ozone is a highly reactive
secondary pollutant. This implies that indoor
ozone generally is caused by penetration of
outdoor ozone (35) and that ozone can be
removed by interior surfaces or by pollutants
generated indoors (2). As a result, indoor
ozone concentrations are generally lower than
ambient concentrations. Indoor–outdoor
ratios in past studies have ranged between
zero and one, with most values between 0.3
and 0.7 (2). Multiple recent analyses found
that indoor exposures are lower in homes
with air conditioning running (35–37).
These ﬁndings imply that the magnitude
of the effect of ambient ozone on health
would likely be inﬂuenced by activity patterns
and air conditioning use. In the extreme, an
individual who spends 24 hr per day in air-
conditioned settings would be expected to
have limited exposure to ozone, even if out-
door concentrations were substantial. This
does not necessarily imply that the epidemio-
logic evidence is uninformative, because day-
to-day variations in ambient concentrations
may still be correlated with variations in levels
of average personal exposures across a city.
The implication for benefit–cost analysis is
that bodies of epidemiologic literature may
not be directly applicable in unstudied cli-
mates. Epidemiologic studies in cities in
which residents spend greater amounts of
time in air-conditioned environments would
be expected to have lower concentration–
response functions, even though the
dose–response functions may be identical. 
Concentration–Response
Evaluation
Approach. As mentioned earlier, we focus on
the health outcomes that contributed signiﬁ-
cantly to ozone beneﬁts in past analyses. In
the CAABCA (3), benefits were not pre-
sented independently for ozone. In the Tier
2 RIA, about 90% of ozone benefits were
associated with minor restricted activity days
and decreased worker productivity (4).
Chronic asthma and respiratory hospital
admissions provided most of the remaining
beneﬁts. We also evaluate ozone-related mor-
tality because it would likely be a signiﬁcant
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ship existed. 
To determine appropriate concentra-
tion–response functions, we gathered all rel-
evant publications addressing each endpoint.
Our approach is to use quantitative methods
to pool studies that we judge to be adequate.
In general, we exclude studies from our
pooled estimate if they do not treat con-
founders appropriately or lack useful quanti-
ﬁed coefﬁcients or standard errors. However,
we use the discarded studies to help interpret
the complete body of literature and deter-
mine whether our quantitative estimates are
representative. In addition, we focus on
studies conducted in the United States when
sufficient studies are available, to minimize
variability related to differences in health
care systems and population characteristics
across countries. 
Epidemiologic studies of ozone have con-
sidered numerous exposure periods, includ-
ing 1-hr maximum, 8-hr average, or 24-hr
average concentrations, with a range of lag
structures and number of days averaged.
Within our analysis, we consider all three
averaging times with the application of con-
stant conversion factors. We assume that 1-hr
maximum concentrations will be 2.5 × 24-hr
concentrations and 1.33 × 8-hr concentra-
tions (38). In addition, we assume that 1 ppb
ozone = 1.96 µg/m3 (conversion at standard
temperature and pressure), although this rela-
tionship will vary slightly in the locations
studied (12,38). The application of these fac-
tors leads to associated uncertainties (because
the relationships among these three measures
vary from place to place and day to day).
This is especially true if one exposure period
is more representative of the true relationship
between dose and effect.
We would expect that the observed con-
centration–response functions would differ
by climate, given the importance of air con-
ditioning for personal exposure. Thus,
pooled literature estimates may not be
directly applicable to our Houston case
study. Ideally, we would use a methodology
such as hierarchic linear modeling that can
incorporate both systematic effects (e.g.,
time activity, air conditioning, temperature,
humidity) and random effects (11). Given
limited studies, we calculate pooled estimates
and use some scaling factors to derive con-
centration–response functions for Houston. 
Within this section, we first discuss the
evidence from cohort studies, including both
mortality and chronic asthma. We discuss
general issues related to the time-series litera-
ture and focus on the evidence for mortality,
hospital admissions, and minor restricted
activity days. 
Cohort mortality. Three major cohort
studies have been published: the Six Cities
study (39), the American Cancer Society
(ACS) study (40), and the Adventist Health
Study of Smog (AHSMOG) (41). For the
former two studies, we focus on the results
from a recent Health Effects Institute (HEI)
reanalysis (42).
AHSMOG (41) evaluated the relation-
ship between air pollution and mortality
risks (lung cancer, cardiopulmonary, nonma-
lignant respiratory, and all-cause) among
6,338 Seventh Day Adventists in California
from 1977 to 1992. Because Seventh Day
Adventists largely abstain from smoking
(validated through questionnaire), one
would expect that respiratory disease rates
would be lower than average. In single-pol-
lutant models, the number of hours of
ozone above 100 ppb was signiﬁcantly asso-
ciated with lung cancer in males [relative
risk (RR) 4.19; 95% confidence interval
(CI), 1.81–9.69] but not with lung cancer
in females or any other cause of death. An
increase in mean ozone concentrations was
not signiﬁcantly associated with any cause of
death (with weak evidence for lung cancer in
males). Multipollutant models were not
reported, but the authors indicated that the
ozone coefﬁcient was reduced in magnitude
with the inclusion of PM10 but was stronger
than the PM10 coefficient. Ozone had a
strong positive correlation with PM10.
In the Six Cities study (39), which fol-
lowed 8,111 white adults in six cities in the
eastern half of the United States for approxi-
mately 14–16 years, there was little variation
in ozone levels across cities (20–22 ppb
annual average in four cities, 28 ppb in two
cities). All relative risks for ozone were below
one and not statistically signiﬁcant in single-
pollutant models (42). The negative rela-
tionship could be related to the inverse
correlation between ozone and PM2.5
(–0.53). Because of the small number of
locations and high correlations between pol-
lutants, no multipollutant model was tested,
but ozone was the only pollutant that did
not demonstrate an association with mortal-
ity in single-pollutant models. 
The reanalysis of the ACS study (42), a
retrospective analysis of a cohort of over
500,000 adults across the United States fol-
lowed from 1982 to 1989, tested numerous
statistical models that included ozone along
with PM and other covariates. In one model
accounting for spatial correlations, ozone
was significantly associated with both all-
cause and cardiopulmonary mortality.
However, across all statistical models, ozone
relative risks were often below one and were
rarely statistically signiﬁcant. Ozone was not
signiﬁcantly related with any cause of mor-
tality in any models including sulfates rather
than PM2.5, and had no relationship with
lung cancer in any model. 
In summary, there is weak and inconsis-
tent evidence of any long-term mortality
effect from ozone. AHSMOG found ozone
to be related to male lung cancer, but the
ACS study (with a larger sample and a more
geographically and demographically repre-
sentative population) found no evidence of
this relationship. The ACS study found
moderately significant effects of ozone on
all-cause and cardiopulmonary mortality in
one statistical model, but these ﬁndings were
contradicted by most reported models and
were not supported by AHSMOG or Six
Cities. We conclude that the current epi-
demiologic evidence does not support long-
term mortality effects from ozone.
However, mechanistic studies demon-
strate potential long-term lung function
decrements associated with ozone exposure.
A recent cohort study found that decrements
in pulmonary function were significantly
associated with mortality rates (43), a find-
ing documented extensively elsewhere
(44–47). Recently, a model of the relation-
ship between lung function and age-speciﬁc
survival probabilities found that small decre-
ments in lung function associated with air
pollution could plausibly explain cohort
mortality findings (48). Thus, although
there is no consistent evidence of long-term
ozone mortality effects at current levels of
exposure, the general notion that these
effects could exist should not be dismissed. 
Chronic asthma. Chronic asthma refers to
the development of new cases of asthma. It
was quantified in both CAABCA and the
Tier 2 RIA, although with the stated caveat in
the Tier 2 RIA that a causal mechanism had
not been established (4). In both cases, the
chronic asthma estimate was based on an
analysis of a subset of the AHSMOG cohort,
in which incident cases of doctor-diagnosed
asthma were compared with 20-year mean 8-
hr average ozone concentrations (49). In
logistic regressions including parameters for
age, education, smoking, and childhood
pneumonia/bronchitis, a 27 ppb increase in
ozone concentrations was signiﬁcantly associ-
ated with increased incidence of asthma in
males (RR 2.09; 95% CI, 1.03–4.16) but not
in females (RR 0.86; 95% CI, 0.58–1.26).
This relationship was unaffected by the inclu-
sion of other pollutants in the model (PM10,
SO4, NO2, and SO2). 
Aside from issues of representativeness,
the U.S. EPA raised other concerns about the
inclusion of this study (4). Information on
ozone levels over time was not used to deter-
mine the concentration–response functions,
information on the accuracy of self-reported
asthma incidence was not considered, and
more than half of subjects dropped out of the
study. Because of these uncertainties, we look
at other relevant studies. 
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asthma development and ozone: a cohort of
children in Southern California (50) and the
Swiss Study on Air Pollution and Lung
Diseases in Adults (SAPALDIA) (51). In the
Southern California investigation (50), a
cohort of 3,676 children in 12 communities
were surveyed by questionnaire in 1993 to
provide a cross-sectional assessment of the
relationship between respiratory morbidity
and air pollution. Two-stage single-pollutant
logistic regressions showed that high-hour
ozone concentrations had little relationship
with asthma prevalence (with a significant
but negative relationship among females). 
The SAPALDIA study (51) was a cross-
sectional investigation of 9,651 adults at
eight sites in Switzerland. Among never-
smokers, there was a negative but statistically
insignificant relationship between ozone
concentrations and current asthma, with a
significant negative relationship between
asthma prevalence and frequency of 30-min
excesses of ozone above 120 µg/m3. Thus,
although cross-sectional studies are less
robust than cohort studies, these two investi-
gations do not support the role of ozone in
the development of asthma. 
Although asthma development caused by
chronic ozone exposure is biologically plausi-
ble, the existing epidemiologic evidence is
weak and contradictory. We would consider
it imprudent to omit this outcome entirely,
but the negative studies (50,51) and the gen-
eral uncertainty must be acknowledged. It is
our judgment that the epidemiologic litera-
ture implies that, for adult males only, we
should place a one-third weight on the
concentration–response function from
AHSMOG and a two-thirds weight on zero.
These weights are our subjective judgments,
based on the negative ﬁndings in two of three
studies and the possible nonrepresentativeness
of the AHSMOG cohort. The AHSMOG
relative risk implies that the incidence rate of
asthma among nonsmoking adult males
increases by 23% (95% CI, 1–40%) per 10
µg/m3 increase in annual average ozone con-
centrations. This is applied to the population
of nonasthmatic and nonsmoking adults
males given a baseline asthma incidence rate
of 0.22% per year (52).
Acute health effects of ozone: general
time-series issues. For time-series investiga-
tions, there are two potentially major con-
founders. PM has been linked with many of
the health outcomes for which we wish to
evaluate ozone effects (5–11). In locations
where PM and ozone concentrations are
positively correlated, it is difficult to deter-
mine the independent effects of ozone. The
correlation between ozone and PM can be
either positive or negative depending on the
setting, implying that ozone effects could be
either understated or overstated in single-pol-
lutant (and perhaps multipollutant) models.
The second potential confounder for
studies examining the relation between air
pollution and human health is weather (53).
Extremely hot or cold days are associated
with greater mortality than occurs during
average weather (54). Weather has also been
associated with hospital admissions for
asthma, a morbidity outcome also associated
with ozone (55). Under hot and humid con-
ditions, the human body has a decreased
ability to cool itself by perspiration or
vasodilation, which can increase the risk of
elevated body temperature and potential
hypotension or heat stroke. The effect of
weather is a particular concern for ozone
because ozone formation is greater under hot
and humid conditions and is therefore more
highly correlated with temperature than are
most other air pollutants. Because both
weather and ozone have plausible mecha-
nisms to increase health risks on high-tem-
perature days, it is difficult to determine
whether the health risks are due to ozone
(53). Complicating matters, the effects of
weather differ somewhat with respect to the
climate of the area; a 90°F day in May will
have a different effect on health in Buffalo
than in Houston. This difference is believed
to be caused by a combination of human
acclimation and activity patterns and differ-
ences in the built environment (i.e., the
prevalence of air conditioning) (56,57). 
Air pollution time-series studies have
attempted to control for weather with vary-
ing degrees of complexity, using terms rang-
ing from temperature indicators to linear and
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Table 1. Summary of U.S. time-series studies of ozone mortality with quantitative multipollutant models
including PM and nonlinear temperature controls. 
Change in mortality 
Location Reported relative Copollutants per 10 µg/m3 of 
Study and dates risk and ozone measure in model 24-hr average ozone
Moolgavkar et al., Philadelphia, PA 1.06 (95% CI, 1.02– TSP, SO2 0.3%
1995 (60) 1973–1988 1.11) per 100 ppb,  (95% CI, 0.1–0.5%)
24-hr average, 1-day
lag
Ito and Thurston,  Cook 1.07 (95% CI, 1.01– PM10 0.9%
1996 (61) County, IL 1.12) per 100 ppb, (95% CI, 0.1–1.4%)
1985–1990 1-hr maximum, 2-day
average
Kelsall et al.,  Philadelphia, PA 1.019 (95% CI, TSP, SO2, NO2, 0.5% 
1997 (58) 1974–1988 1.007–1.031) per 20 CO (95% CI, 0.2–0.8%)
ppb, 24-hr average, 
2-day average
Moolgavkar et al., Cook 1.014 (95% CI, PM10, SO2 0.7%
2000 (62) County, IL 1.006–1.023) per 10 (95% CI, 0.3–1.1%)
1987–1995 ppb, 24-hr average,
1-day lag a
Pooled estimate 0.5% 
(random effects model) (95% CI, 0.3–0.7%)
aAuthor reports results for lags between 0 and 5 days; reported result reﬂects maximum ozone impact (ozone was signiﬁ-
cant for 0–2 days, nonsigniﬁcant for 3 days and beyond). 
Figure 1. Time-series ozone mortality studies included in our quantitative analysis, along with pooled esti-
mates from past investigations. 
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Moolgavkar et
al., 1995 (60)
(Philadelphia)
Kelsall et
al., 1997 (58)
(Philadelphia)
Ito and Thurston,
1996 (61)
(Cook County)
Moolgavkar et
al., 2000 (62)
(Cook County)
Pooled
estimate
Thurston and
Ito, 2001 (12)
pooled
estimate, all
studies
Thurston and
Ito, 2001 (12)
pooled
estimate,
nonlinear
temperature
Tier 2 RIA
pooled
estimate
[Thurston and
Ito, 2001 (12)]nonlinear temperature and humidity terms to
synoptic air mass classification (58,59).
Given the nonlinear relationships and com-
plex interactions, simpler weather terms may
not adequately characterize the true relation-
ship between ozone and health. Interestingly,
a recent study noted that past ozone time-
series studies tended to report lower relative
risks when simpler methods were used to
control for temperature (12). Because this has
significant implications for interpreting the
epidemiologic literature, there is clearly a
need for continued study of whether current
statistical methods can rule out weather as a
confounder of ozone health effects. 
Time-series mortality. To determine the
relationship between ozone and daily mor-
tality, we conducted a broad survey of the
time-series mortality literature. We evaluated
50 time-series studies from 39 published
articles for their relevance and applicability,
largely drawn from studies evaluated in a
recent PM meta-analysis (11) and from a lit-
erature search on more recent publications.
Our literature survey included all studies
incorporated into the recent CAABCA and
Tier 2 RIA (3,4) and is available from the
authors upon request. 
Of these 50 estimates, we eliminated all
but four using simple screening criteria.
Reasons for exclusion included no mention
of ozone (19 estimates), studies outside the
United States (13), use of linear temperature
terms (1), lack of quantitative ozone esti-
mates in any model (5) or in multipollutant
models (3), lack of models for ozone that
included PM (3), or lack of reported relative
risks or standard errors (2). We are left with
four studies of either Cook County, Illinois,
or Philadelphia, Pennsylvania (58,60–62),
with overlapping time periods. When we
include studies outside the United States, we
add two studies from Europe (63,64). By
way of comparison, the Tier 2 RIA evaluated
28 studies and eliminated all but nine (4).
Four of these studies were within the
United States: the three studies cited above
(58,60,61) that were published at the time
of the Tier 2 RIA and a study that consid-
ered temperature as a linear term (65).
Among our six applicable studies, only the
two Cook County studies had PM10 as a
particulate matter measure, with no studies
using PM2.5 and the remaining studies using
either total suspended particles (TSP) or
black smoke. 
All four U.S. studies concluded that
ozone was a statistically signiﬁcant predictor
of premature mortality (Table 1). We pool
the four studies using a random effects
model (66), yielding an estimated 0.5%
increase in premature deaths per 10 µg/m3
increase in 24-hr average ozone concentra-
tions (95% CI, 0.3%, 0.7%) (Figure 1). If
we included the two non-U.S. studies, our
pooled estimate would increase slightly to
0.6% (95% CI, 0.4%, 0.9%). Although not
stated explicitly, the Tier 2 RIA (and other
recent U.S. EPA impact assessments) used a
value of 2.9% per 100 ppb increase in 1-hr
maximum ozone (12), which is similar to
our pooled value given standard conversions.
Our function can be applied to the all-age
background annual mortality rate in the
United States of 0.0086 (67).
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Table 2. Summary of all U.S. time-series studies excluded from pooled analysis in Table 1 that included ozone mortality and used nonlinear temperature controls. 
Correlation Change in mortality
Location Reported result with PM per 10 mg/m3 of
Study and dates and ozone measure Problem term 24-hr average ozone
Dockery et al., St. Louis, MO β = 0.00029 per ppb, No copollutants — 0.1% (95% CI, –0.6–0.9%)
1992 (70) 1985–1986 24-hr average (95% CI,
–0.0012–0.0018)a
Dockery et al., Kingston, TN β = –0.00065 per ppb,  No copollutants — –0.3% (95% CI, –2.1–1.5%)
1992 (70) 1985–1986 24-hr average (95% CI,
–0.0041–0.0028)a
Schwartz, Detroit, MI Ozone “highly No copollutants,  — 0% (95% CI, –2–2%)b
1991 (69) 1973–1982 insigniﬁcant” not quantiﬁed
Shumway et al., Los Ozone not signiﬁcant in  Not quantiﬁed –0.12 0% (95% CI, –2–2%)b
1988 (68) Angeles, CA models, no quantitative (KM)
1970–1979 estimates, highly
correlated with 
temperature
Gwynn et al., Buffalo, NY β = 0.000585 per ppb, No copollutants 0.68 0.3% (95% CI, –0.1–0.7%)
2000 (72) 1988–1990 24-hr average, 2-day lag (PM10)
(95% CI, –0.00015–
0.0013)a
Mar et al., Phoenix, AZ Ozone nonsigniﬁcant Not quantiﬁed –0.20 0% (95% CI, –2–2%)b
2000 (73) 1995–1997 (p < 0.10) (PM2.5)
Moolgavkar et al., Los Angeles, CA Ozone nonsigniﬁcant Not quantiﬁed  0.04 0% (95% CI, –2–2%)b
2000 (62) 1987–1995 (PM2.5)
Moolgavkar et al., Maricopa Ozone nonsigniﬁcant Not quantiﬁed  0.00 0% (95% CI, –2–2%)b
2000 (62) County, AZ (PM10)
1987–1995
Lippman et al., Detroit, MI 1.0247 (95% CI, 1.0025– No copollutants 0.36 0.3% (95% CI, 0.0–0.7%)
2000 (74) 1985–1990 1.0473) per 36 ppb 24-hr (PM10)
average, 1-day lag
Lippman et al., Detroit, MI 1.04 (95% CI, 0.9667– No copollutants 0.49 0.7% (95% CI, –0.6–2.0%)
2000 (74) 1992–1994 1.1188) per 28 ppb 24-hr (PM2.5)
average, 1-day lag
Fairley, 1999 (71) Santa Clara, CA 1.05 (nonsigniﬁcant)  PM2.5, CO, NO2
–0.15  1.4% (95% CI, –0.4–3.2%)c
1989–1996 per 33 ppb 8-hr average in model; no CI (PM2.5)
given
Pooled estimate from Table 1 0.5% (95% CI, 0.3–0.7%)
Pooled estimate including above studies 0.4% (95% CI, 0.3–0.5%)
Pooled estimate, minimum variance in unquantiﬁed studies 0.3% (95% CI, 0.1–0.6%)
KM, optical measure of carbonaceous particles.
aRegression coefﬁcient reported; RR = exp(βx), where x is the concentration increment. bWe assume 0% for central estimate given no quantiﬁed effect; variance assumed to be maximum of all
studies in table (minimally informative). cEight-hour average converted to 24-hr average using ratio of 2.5/1.33; variance assumed to be maximum of all studies in table (minimally informative).Although these four studies provide
weak epidemiologic support for ozone mor-
tality, our estimate could be biased because it
excludes studies that found ozone to be
insigniﬁcant but did not fulﬁll our inclusion
criteria. Studies that found ozone to be
insignificant in single-pollutant models
would have excluded ozone from multipol-
lutant analyses, and it would be inappropri-
ate to discount this information. Similarly,
studies that focused on other pollutants and
considered ozone as a confounder provide
relevant information. Thus, we examine the
excluded estimates that used nonlinear tem-
perature terms to determine whether they
signiﬁcantly inﬂuence our pooled estimate. 
In Table 2, we present an expanded list
of U.S. studies with their reported findings
and limitations (62,68–74). For the studies
in which ozone was stated to be insigniﬁcant
without quantiﬁed estimates (62,68,69,73),
we assume a central estimate of zero and test
variances equivalent to both the minimum
and the maximum reported in the studies in
Table 2. Including the insignificant studies
with the above assumptions does not materi-
ally influence either the central estimate or
the confidence intervals. However, the fact
that nearly all of the studies in Table 2 ﬁnd
ozone not to be a significant predictor of
premature mortality (including all studies in
warmer climates) gives one pause in using
our pooled estimate as a representative mea-
sure of ozone mortality risks. The lack of sig-
nificance could demonstrate either that no
causal relationship exists or that the low
indoor–outdoor ratios imply that many
studies have insufﬁcient statistical power to
detect the population effects of ozone. 
In summary, the time-series mortality
literature shows a significant relationship
between ozone and premature mortality
when PM and nonlinear temperature terms
are incorporated, but limited information is
available in warmer climates. Possible con-
founding by weather leaves lingering doubt
about whether the ozone ﬁndings are causal,
an issue that would be difficult to resolve
epidemiologically. Evidence of biologic
mechanisms and the documented morbidity
effects lend credence to the possibility of
premature deaths from ozone exposure, but
the uncertainties are greater than reﬂected in
pooled literature estimates. 
Hospital admissions. Analysts have
looked at both respiratory and cardiovascular
categories of hospital admissions to deter-
mine whether an association with ozone
exists. The major respiratory outcomes
include acute bronchitis, pneumonia and
influenza, COPD, and asthma. Categories
examined for cardiovascular outcomes
include ischemic heart disease, dysrhythmias,
and heart failure. For a control, analysts have
examined outcomes believed to be com-
pletely unrelated to air pollution, such as
appendicitis.
Unlike PM and CO, ozone has not
shown a consistent association with cardio-
vascular hospital admissions (75–78), and
we do not consider this outcome further.
However, signiﬁcant associations have been
observed for respiratory outcomes, especially
in the spring and summer. As identiﬁed by
Thurston and Ito (79), three main categories
of studies exist: a group of studies conducted
in New York, Ontario, and Montreal look-
ing at major respiratory outcomes for all
ages, the same group of studies restricted to
asthma, and a group of Medicare-based
studies in the United States. The identiﬁed
studies included all studies incorporated into
past benefit–cost analyses, except a recent
study of Toronto that found risks similar to
those in past studies (80). The National
Morbidity, Mortality, and Air Pollution
Study (81) did not evaluate ozone as an
independent predictor of hospital admissions
but found it to be insigniﬁcant as a stage-2
parameter in PM models. 
Thurston and Ito (79) combined the
studies in each category using a random
effects model, with each contributing study
representing a different population in location
or time. Since daily 1-hr maximum ozone was
the variable most often used, they converted
studies using other measures based on infor-
mation reported in each study or using
default conversion factors as described earlier.
All three categories showed similar
results. The “all respiratory/all age” category
of studies yielded a combined RR of 1.18
(95% CI, 1.10–1.26) per 100 ppb increase
in daily 1-hr maximum ozone. The
“asthma/all age” category yielded a com-
bined RR of 1.18 (95% CI, 1.07–1.30),
with Medicare-based studies yielding a com-
bined RR of 1.19 (95% CI, 1.1–1.26).
Although hospital admission patterns could
differ between the United States and Canada
(given differences in health care systems), the
pooled estimates in all categories were simi-
lar for both countries. 
Because these relative risks are almost
identical, we consider only “all respiratory/all
age” for benefit–cost analysis (because
asthma admissions or admissions for the
elderly are a subset of this category). The
pooled relative risk implies a 2% increase in
respiratory hospital admissions (RHA) per
10 µg/m3 increase in 24-hr average ozone
concentrations (95% CI, 1–3%). If only the
U.S. estimates were used, the estimate would
be reduced slightly to 1.7% (95% CI,
1.1–2.3%). Because the estimates are similar,
we use the U.S.-based estimate for our case
study for simplicity and consistency. As for
time-series mortality, this estimate is based
exclusively on studies in cold climates. Two
Medicare-based studies listed by Thurston
and Ito (79) were based in a warmer climate
(Birmingham, Alabama), and both found no
significant relationship. The all-age back-
ground annual hospital admission rate for
the respiratory categories in the epidemio-
logic studies is 0.009 (82). 
Restricted activity days. The term
“restricted activity day” (RAD) is deﬁned as
any day in which an individual is forced to
reduce his or her normal activities because of
acute or chronic conditions (83). Minor
restricted activity days (MRAD) are days
with reduced activity that do not result in
work or school loss or bed disability, and res-
piratory restricted activity days (RRAD) are
RADs when acute respiratory symptoms
were reported. 
Only one published study used in past
beneﬁt–cost analyses evaluated the relationship
between RAD and ozone (84). This study
determined RAD between 1976 and 1981
from the annual Health Interview Survey, a
nationally representative cross-sectional sample
of 50,000 households. Restricted activities
were taken from 2-week recall surveys of
working adults and were regressed against
PM2.5 (derived from airport visibility data)
and ozone in each year. Ozone concentrations
were highly correlated with the temperature
term but not with PM2.5. For RRAD, ozone
was not statistically signiﬁcant in any year. For
MRAD, in multipollutant models the authors
reported that an inverse-variance weighting
yielded a 0.2% increase per microgram per
cubic meter increase in 2-week average 1-hr
maximum ozone concentrations. No uncer-
tainty bounds were reported, but a simple
variance estimate based on reported standard
deviations by year yields a 95% confidence
interval of 0.1–0.3%. 
Although this study found a significant
and plausible relationship, some statistical
issues make the estimate somewhat uncertain.
First, temperature is incorporated linearly and
is highly correlated with ozone, which
decreases our certainty that we are properly
measuring the independent ozone effect. In
addition, the reported pooled value is based
on the assumption that the three years with-
out positive and signiﬁcant estimates should
be assigned a value of zero (the regression
coefficient is significantly negative in 1977
and 1981 and is positive but nonsigniﬁcant in
1976). There is reason to believe that non-
signiﬁcant slopes should be included as calcu-
lated because a regression across all 6 years
would incorporate these data. Using the
reported central estimates and standard devia-
tions for all years reduces the concentration–
response to 0.1% (95% CI, 0.05–0.2%). 
Although no other studies have evalu-
ated MRAD, other epidemiologic studies of
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respiratory symptoms have been used for
comparison. In the Tier 2 RIA (4), a study
by Krupnick and colleagues (85) was pooled
with the MRAD estimate to yield a single
estimate of ozone restricted activities. This
study found that a 1% increase in high-hour
ozone concentrations corresponded with a
0.073% increase in any of 19 respiratory
symptoms (a 0.04% increase per microgram
per cubic meter increase in high-hour ozone).
Comparability with the MRAD estimate is
impaired by the differences in averaging time,
symptom severity, and study population.
However, the concentration–response is
reported to be greater for MRAD, the more
severe health outcome. Because of differences
in health effects, study populations, and
treatment of confounders, pooling these two
studies does not seem appropriate. 
In summary, the magnitude of the
impact of ozone on MRAD should be con-
sidered somewhat uncertain, given that only
one older study with statistical issues is avail-
able. Alternative methods to pool the six
years of data tend to decrease the effect esti-
mate, whereas incorporation of nonlinear
temperature terms could increase the effect
estimate (79). It is our judgment that a 0.1%
increase in MRAD per µg/m3 increase in 2-
week average 1-hr maximum ozone concen-
trations (equivalent to a 3% increase per 10
µg/m3 increase in 24-hr concentrations) is
an appropriate best estimate. A 0.2%
increase, reflecting the reported estimate
(84) or the possible inﬂuence of linear tem-
perature controls, would be an upper bound.
A lower bound of 0.05% would reflect the
19 symptom ﬁndings (85). We place proba-
bility weights of 50% on the central estimate
and 25% on the upper and lower bounds,
and we use a background MRAD rate of 7.8
per person per year (84). 
Case Study: Estimation of
Concentration–Response
Functions for Houston
For a case study of benefits from ozone
reductions in Houston, no epidemiologic
studies are currently available for the city or
for cities with similar climates. Because of
differences in exposure patterns, it may not
be appropriate to directly apply ﬁndings from
colder locations. Our approach is to deter-
mine “scaling factors” that represent personal
exposures per unit concentration, which can
be used to extrapolate ﬁndings from studies
in different climates. Our model is a first
approximation, and we provide broad uncer-
tainty bounds to reﬂect this fact.
Based on the exposure assessment litera-
ture for ozone, key components of an expo-
sure-related scaling factor are time spent
indoors versus outdoors and time spent
indoors with and without air conditioning.
For simplicity, we derive our central estimate
of mean personal exposure using a simpliﬁed
microenvironmental model (37). In our
model,
E = CoFo + (Io x Co)Fi ⇒ SF = Fo + IoFi,
where E = mean personal exposure concen-
tration (micrograms per cubic meter); Co =
outdoor ozone concentration (micrograms
per cubic meter); Fo = fraction of time spent
outdoors; Fi = fraction of time spent indoors
without air conditioning; Io = indoor/out-
door ratio without air conditioning; SF =
scaling factor. This model assumes that time
spent indoors with air conditioning results in
minimal ozone exposure (2,37). 
We assume that the indoor-outdoor ratio
without air conditioning (Io) equals 0.5 (2).
For simplicity, we assume that ozone expo-
sures while in transport are equivalent to
outdoor concentrations and that all time
spent indoors is equivalent to residential
indoors. We use national average time-activ-
ity pattern data (given small regional differ-
ences) to estimate that Fo = 0.14 (34). To
determine Fi, we need to know both the
prevalence of air conditioning and the fre-
quency of its use. We assume that air condi-
tioning is used any day when the maximum
temperature exceeds 90°F (a simplification
that ignores humidity). 
Thus, our ﬁnal scaling factor formula is
SF = 0.14 + (0.5)(0.86)
× [(1–AC) + AC(1 – HOT)],
where AC = prevalence of air conditioning
and HOT = fraction of days with maximum
temperature above 90°F. This formula
reflects the fact that time can be spent in
non–air-conditioned homes either when a
home lacks air conditioning or when the
outside temperature is low.
To derive the scaling factors, we estimated
the prevalence of air conditioning from the
American Housing Survey for a year represen-
tative of the epidemiologic study dates for all
U.S. studies (86). Temperature values were
taken from National Climatic Data Center
reports from each city for all study dates (87).
Using the derived scaling factors (Table
3), we found the personal exposures per unit
concentration to be almost identical in every
location but Houston, where the scaling fac-
tor is approximately 25% lower. This differ-
ence is perhaps less than anticipated or
indicated by the limited epidemiologic evi-
dence. The small difference is largely related
to our assumption that air conditioning is
used across only a fraction of the year in all
settings. To bound our scaled concentra-
tion–response estimates for Houston appro-
priately, we consider two extremes. As an
upper bound, we assume that no scaling is
required. As a lower bound, we assume that
air conditioning is on at all times when pre-
sent, which makes our scaling factor equal to
0.14 + 0.43(1–AC). 
For time-series mortality and RHA in
Houston, our central estimate is the central
estimate when studies are pooled using the
scaling factor adjustment. Our lower bound
is the 5% confidence value with the lower
bound scaling factor, and our upper bound is
the 95% confidence value with no scaling
factor. We assign probability weights of 50%
to the central estimate and 25% to the
extremes. Similarly, for MRAD, we apply no
scaling, the central scaling factor, and the
lower bound scaling factor to the derived
upper bound, central estimate, and lower
bound (respectively), assigning the same
probability weights. For chronic asthma, zero
remains our lower bound with a two-thirds
weight, and we consider the lower bound
scaling factor applied to the AHSMOG cen-
tral estimate to be our central estimate, with
an upper bound as the unscaled AHSMOG
central estimate. All values and weights are
presented in Table 4. 
Monetary Valuation
Premature mortality. There are two primary
competing philosophies about the appropri-
ate approach for valuing reductions in pre-
mature deaths. The value of statistical life
(VSL) approach theoretically represents a
“willingness-to-pay” (WTP) framework, in
which the dollar amount an individual is
willing to pay to avoid a small increase in
pollution-based risk is used to value changes
in population deaths caused by pollution.
The VSL approach is well grounded in eco-
nomic theory and has been the primary
approach used in recent integrated assess-
ments (3,4,88–90), but the lack of a market
for mortality risks from air pollution implies
that WTP in this context must be extrapo-
lated from estimates for other settings.
Alternatively, the medical decision-mak-
ing ﬁeld has used measures such as quality-
adjusted life years (QALYs) to compare the
cost-effectiveness of different medical inter-
ventions. QALYs account for self-reported
health status and life expectancy, allowing
characteristics of at-risk populations to be
considered, but QALYs are not directly
applicable to benefit–cost comparisons.
Values of approximately $100,000 per
QALY are often used as a rough upper
bound for the desirability of interventions
(91). There is an active debate about the rela-
tive merits of VSL and QALY frameworks,
given numerous implications about the rela-
tive values of health outcomes and risks to
subpopulations. Because resolution of this
issue is beyond the scope of our article, we
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frameworks. 
For VSL, recent assessments have used an
estimate derived from a group of 26 “policy-
relevant” studies summarized in Viscusi (92),
which had values ranging from $1 million to
$11 million (in 1997 dollars). Twenty-one of
the 26 studies consider the additional com-
pensation demanded in the labor market for
riskier jobs, with the remaining five studies
directly surveying individuals (contingent
valuation studies). Although U.S. EPA has
recognized the possible importance of adjust-
ing these estimates, its recent benefit–cost
studies (3,4) have used an unadjusted VSL
pooling the 26 studies (mean of $5.8 million,
standard deviation of $3.2 million). 
For the application of these VSL esti-
mates to be appropriate, they must accu-
rately represent what people who are likely
to be affected by air pollution would be will-
ing to pay to reduce their risk of dying
within a speciﬁed time period. There is con-
siderable uncertainty regarding the appropri-
ate way to adjust VSL between labor market
or general population contingent valuation
(CV) studies and air pollution applications
(93–95). This uncertainty is predicated
largely on the assumptions that a) people
who are dying from air pollution differ from
the populations studied in the labor market
and CV literature; and b) that VSL will be
different for these populations (because of
age, current health status, willingness to
accept risk, or other factors). 
On the ﬁrst point, the populations stud-
ied in the labor market and CV literature are
likely much younger and healthier than the
populations affected by air pollution. Recent
literature has demonstrated that elderly indi-
viduals with serious pre-existing pulmonary
or cardiovascular disease are at greater risk
from PM (96). Although we are not aware of
a similar investigation for ozone, the fact that
ozone likely has a disproportionate impact on
individuals with COPD or other respiratory
diseases lends credence to this argument. 
For the second point, we must be able to
extrapolate from young-to-middle-aged
workers who accept hazardous jobs (and
therefore might have lower VSL than those
who do not) to older individuals who are
likely in worse health. Several researchers
(97–100) have examined how tradeoffs
between income and mortality risk are
expected to vary over the life cycle (91). This
pattern would be inﬂuenced by two oppos-
ing factors: The number of future life-years
at risk declines with age, but so does the
opportunity cost of spending on risk reduc-
tion. Shepard and Zeckhauser (98) estimate
that VSL is about half the level at age 65 as at
age 40. On the other hand, Ng (100) argues
that people discount their future utility at a
rate smaller than the market interest rate,
and therefore that VSL could conceivably
rise until a relatively old age (e.g., 65 or so)
before it would begin to fall. 
Given this uncertainty, it is difficult to
support a specific adjustment to the VSL
reported by the EPA based on any possible
diminished length or quality of life. An age-
adjusted VSL would clearly be more appro-
priate than an unadjusted value, but given
uncertainties regarding the magnitude and
even direction of this effect, the EPA mean
value of $5.8 million is one reasonable esti-
mate for the valuation of premature mortality. 
Alternatively, a QALY-based approach
would take into account the remaining life
expectancy and health status of individuals
at risk from air pollution. We focus only on
estimating the average length of life lost in
ozone-related deaths, which is quite uncer-
tain. This is similar to using the method of
value of statistical life year (VSLY). Using
this concept, we assign a constant value per
year of life lost, although the idea that VSLY
would be constant is inconsistent with stan-
dard economic theory (because the opportu-
nity cost of spending depends on age).
An upper bound on life-years lost would
assume that persons dying from acute ozone
exposure have a life expectancy equal to their
age cohort. We make a simplifying assump-
tion that these are all individuals with
COPD. Given U.S. life expectancies of 14
years at age 70, 8 years at age 80, and 4 years
at age 85, this approach would yield an esti-
mate of approximately 10 years of lost life
per death given the age distribution of
deaths for COPD in the U.S. population
(101). Because individuals with COPD
would be expected to have a shorter life
expectancy than their age cohort, this is
likely an overestimate. 
A more realistic estimate of life expectancy
loss would take into account the poor health
of at-risk persons relative to their age cohort.
A recent statistical analysis concluded that
the life expectancy loss associated with acute
PM exposure is at least several months for
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Table 3. Derivation of scaling factors for a hypothetical case study of ozone concentration reductions in
Houston, TX. 
Residential air
conditioning Percentage of  Scaling factor
prevalence  days with maximum (lower bound
Health effect, study site/years (year of data) temperature > 90°F estimate)
Time-series mortality
Philadelphia, PA;1973–1988 69% (1982) 7% 0.96 (0.41)
Cook County, IL;1985–1995 71% (1987) 5% 0.97 (0.39)
Chronic asthma
San Francisco, San Diego,  34%a 1%a 1.00 (0.71)
Los Angeles, CA; 1977–1992
Respiratory hospital admissions
Buffalo, NY; 1988 27% (1988) 5% 0.99 (0.77)
New York City; 1988  57% (1987) 7% 0.97 (0.51)
Minor restricted activity days
United States,1976–1981 50% (1978)  10% (estimated) 0.96 (0.57)
Houston, TX 96% (1995) 30% 0.75 (0.17)
aAverage across all three cities, given no information about number of participants in each location. Air conditioning
prevalence taken from 1985 San Francisco (19%), 1989 Los Angeles (50%), and 1987 San Diego (33%) data.
Table 4. Concentration–response functions for a hypothetical case study of ozone concentration reduc-
tions in Houston (% increase in outcome per 10 µg/m3 increase in 24-hr average ozone concentrations). 
Affected Lower bound Central value Upper bound
Outcome population (weight) (weight) (weight)
Time-series mortality All ages 0.2% (0.25) 0.4% (0.50) 0.7% (0.25)
Chronic asthma incidencea Nonasthmatic,  0% (0.67) 6% (0.17) 23% (0.17)
nonsmoking
males, age ≥ 27
Respiratory hospital admissions All ages 0.4% (0.25) 1% (0.50) 2% (0.25)
Minor restricted activity daysb Age ≥ 18 0.4% (0.25) 2% (0.50) 5% (0.25)
Weights are subjectively determined by authors, based on strength of literature, consistency, and representativeness.
aBased on twenty-year average concentrations; percentage increase refers to incident cases of asthma (baseline rate
of 0.22%). bBased on two-week average concentrations.
Table 5. Summary of derived monetary valuations of ozone-related health outcomes (in 1997 dollars). 
Lower bound Central value Upper bound
Outcome (weight) (weight) (weight)
Time-series mortality $100,000 (0.5) – $5,800,000 (0.5)
Chronic asthma incidence $15,000 (0.25) $31,000 (0.5) $60,000 (0.25)
Respiratory hospital admissions $10,000 (0.25) $20,000 (0.5) $40,000 (0.25)
Minor restricted activity days $20 (0.25) $47 (0.5) $75 (0.25)all-cause mortality, but on the order of weeks
for COPD (102). Even if the all-cause mor-
tality ﬁnding holds for ozone, current statisti-
cal methods cannot distinguish whether the
air pollution deaths involve an average loss of
only three months or a longer loss of life.
Another relevant data point: If the average
person dying from ozone exposure had previ-
ously been admitted to an ICU for COPD,
then evidence from the medical literature
tells us that the life expectancy loss would be
on the order of months (103).
Given the uncertainties in the loss of life,
it is difﬁcult to provide a deﬁnitive QALY-
based value. A reasonable estimate would be
that the life expectancy lost per death is on
the order of a year, implying that a QALY
approach would yield an economic value of
approximately $100,000 per ozone-related
death. This may be an underestimate for
elderly individuals who have a reduced
opportunity cost of spending, as illustrated
by a recent CV study that found VSL among
individuals over age 70 to be approximately
$500,000, with similar values for those in
poorer health (104). Furthermore, because
this study was conducted on Canadian indi-
viduals (and converted to U.S. currency),
the existence of national health care may
imply that the study subjects may be willing
to pay less for risk reduction than would
U.S. subjects. 
It is clear that there is a broad range
between our lower bound QALY-based esti-
mate ($100,000) and our upper bound VSL-
based estimate ($5.8 million), with each
estimate having significant uncertainties.
Clearly, the degree of belief placed on the
appropriate valuation framework will strongly
influence any benefit estimation and policy
decision. For simplicity, we assign each esti-
mate a weight of 50%, but we strongly
encourage that any beneﬁt–cost analysis eval-
uate this weighting carefully and determine
whether policy formulations are driven by the
weights placed on these valuations. 
Chronic asthma. For chronic asthma,
two valuation studies were cited by U.S.
EPA (105,106). In the first investigation,
both dichotomous choice and bidding game
methods were used to determine WTP for a
cure for asthma, with mean monthly values
of $343 and $189, respectively. In dichoto-
mous choice, the respondent accepts or
rejects single prices for a risk reduction, with
the WTP estimated by varying the price
across respondents. Bidding game changes
the price for the respondent until the maxi-
mum WTP is reached (either by increasing
or decreasing the price). U.S. EPA (4) used
the bidding game value, assuming a 5% dis-
count rate and average male life expectancy,
to yield a value of $37,000 per case (in 1997
dollars). In the second study (106), the
authors reported WTP values ranging from
$1,000 to $3,700 per year (depending on
model form), with a value of $1,500 selected
by the U.S. EPA (corresponding to $23,000
per case). The U.S. EPA then used a triangu-
lar distribution centered at $31,000 for its
beneﬁt–cost evaluation. 
We feel that this triangular distribution
underestimates the uncertainty in the valua-
tion of chronic asthma, partly because of sig-
niﬁcant issues related to the generalizability of
the two WTP studies. The former analysis
considered a convenience sample of 69
patients in Kentucky, whereas the latter study
included 51 individuals from the same region
of Kentucky as well as 95 people recruited
from an internet newsgroup for asthma suffer-
ers. Because of this, O’Conor and Blomquist
(106) state explicitly that “the sample was con-
venience-based and not readily suitable for
drawing inferences regarding the general pop-
ulation” (p. 673). In addition, there are uncer-
tainties associated with the statistical model,
the discount rates, and the time horizons.
We select the U.S. EPA estimate of
$31,000 as our central estimate, given a lack
of systematic bias in the uncertainties
described above (Table 5). As our lower
bound, we consider a cost-of-illness (COI)
estimate, which we would expect to be less
than the WTP to cure the disease. A recent
assessment of U.S. medical costs found that
adults with asthma incur an average of
approximately $800 per year in direct (doc-
tor visits and medication) and indirect (work
days lost) expenses (107). If we assume this
cost to remain across the lifetime of the indi-
vidual, then a reasonable COI estimate for
the elimination of asthma in an adult would
be approximately $15,000 (in 1997 dollars,
5% discount rate). Our upper bound is
taken from the highest central value reported
by O’Conor and Blomquist (106), which
translates to approximately $60,000 per case. 
Hospital admissions. For hospital admis-
sions, no WTP studies were included in the
U.S. EPA assessments or were identified in
our literature search. Thus, the U.S. EPA
assessments (3,4) estimated the COI associ-
ated with “all cause” RHA to be $10,000,
based on medical costs and lost work time.
However, direct application of COI values
likely underestimates the total social costs of
hospitalization. Studies of both WTP and
COI for changes in asthma symptoms
(108,109) or angina (110) found that the
ratio of WTP to COI ranged from 1.3 to 4.
Thus, although the U.S. EPA opted not to
apply a scaling factor to the RHA COI esti-
mates, a realistic best estimate would likely
be a factor of two greater than the COI
($20,000). We consider the COI ($10,000)
as a lower bound and place an upper bound
at four times the COI ($40,000) (Table 5). 
Minor restricted activity days. To our
knowledge, no studies have directly evalu-
ated the WTP to avoid an MRAD. The esti-
mate generally used is based on WTP
estimates for a three-symptom combination
of coughing, throat congestion, and sinusitis
(111). In 1997 dollars, the WTP estimate
was $47, and this estimate was bounded by
considering a lower bound of $20 for the
mildest symptom evaluated (eye irritation)
and selecting an upper bound of $75 to ﬁt a
triangular distribution (52). The upper
bound is somewhat arbitrary, but it is argued
(52) that an MRAD should be valued as less
than a work-loss day ($104 in 1997 dollars).
Although there are uncertainties associated
with the application of WTP for selected
symptoms rather than speciﬁc restrictions of
activity, the U.S. EPA distribution seems
appropriate, and an accurate WTP estimate
for MRAD would be unlikely to extend
beyond this range (Table 5). It is worth not-
ing that WTP is generally a concave func-
tion of duration of morbidity, which may
imply that these estimates could vary some-
what for episodes with different durations. 
Discussion
Our overview of the relevant literature for
ozone benefit–cost analyses raises a few
major issues. Although the epidemiologic lit-
erature yields coherent and plausible find-
ings, interpretation and extrapolation are
impaired by the small number of available
studies and the lack of geographic diversity.
Since time–activity patterns and the presence
of air conditioning can influence ozone
exposures, it is difficult to determine
whether study ﬁndings are applicable across
settings. Based on the exposure assessment
literature and limited information from epi-
demiologic investigations, the benefits of
ozone concentration reductions appear to be
lower in hot and humid climates with preva-
lent air conditioning. 
There are a few disquieting implications
of this conclusion. First, although it appears
that ozone can influence respiratory health
given sufﬁcient exposure, beneﬁt–cost analy-
ses based on values reﬂecting air condition-
ing levels may conclude that controls are not
cost-effective. However, individuals in these
warmer climates who spend most of their
day outdoors or who do not have air condi-
tioning (likely lower-income individuals)
would be placed at risk from a policy limit-
ing ozone controls. This has equity concerns
and it violates the Clean Air Act concept of
protection of “sensitive or susceptible indi-
viduals or groups” (112). Furthermore, an
optimal policy based on the premise of lower
indoor exposures might argue that suscepti-
ble individuals should stay indoors as much
as possible to avoid known health impacts in
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ers would feel some unease with that conclu-
sion, and the ubiquity of indoor air
pollution might imply that these individuals
would ultimately be worse off.
Using the estimates and probability
weights in Tables 4 and 5, we can calculate a
simple distribution of health beneﬁts and the
leading contributors to uncertainty (Figure
2). Our central estimate is that a 1-µg/m3
decrease in annual average ozone concentra-
tions would lead to an annual benefit of
approximately $10 per individual (95% CI,
$0.70–40). Nearly 90% of this total is
related to premature mortality, with MRAD
as the next largest effect. By way of compari-
son, in the Tier 2 RIA, annual health bene-
fits projected for 2030 for ozone-related
endpoints were approximately $260 million
[Table VII-12 (4)]. The population average
concentration reduction from May to
September was 0.5 ppb, which translates to
0.4 µg/m3 annual average if formation is
minimal in other months. Given a projected
at-risk population of 345 million (4), health
beneﬁts are approximately $2/person/µg/m3
annual average. Our central estimate is
greater due to the inclusion of mortality.
Although the probability distribution has
limited interpretability given our discrete
weighting approach, it is apparent that the
uncertainty regarding the appropriate mone-
tary value for mortality contributes most to
overall uncertainty, followed by the concen-
tration–response function for mortality
(Figure 2). 
Future research should focus on those
health outcomes and topics for which reduced
uncertainty or different values could lead to
different policy options. Although it is difﬁ-
cult to determine the key areas of research
without a comprehensive value-of-informa-
tion analysis, our initial benefit estimation
and preliminary evaluation of uncertainty
lead us to conclude that the following studies
are warranted:
• Willingness-to-pay studies targeted at indi-
viduals susceptible to air pollution health
risks (e.g., elderly individuals with COPD)
• Further research on the life expectancy loss
associated with ozone-related mortality
• Epidemiologic investigations centered on
ozone in a range of climates, especially
time-series studies of premature mortality
and minor restricted activity days (includ-
ing issues of the relevant exposure win-
dow/averaging time)
• Investigations of indoor/outdoor/personal
exposure patterns in a range of geographic
settings, to strengthen our knowledge of
the relationship between concentration and
exposure as a function of air conditioning,
climate, and activity patterns.
As mentioned earlier, these conclusions
are based on our interpretation of the existing
literature. Although we feel that the general
conclusions of our analysis are supported by
the literature we surveyed, other researchers
might derive different quantitative estimates
and characterizations of uncertainty. The
goal of our investigation was to flag the
important questions and to make a first
attempt at addressing these questions, but a
larger-scale effort involving experts from all
disciplines is warranted to reﬁne this analysis. 
Although we have broadly considered
the major issues related to ozone beneﬁt esti-
mation, a comprehensive beneﬁt–cost analy-
sis should consider multiple additional
dimensions. Because ozone is a secondary
product of reactions between NOx and
volatile organic compounds, any control
strategy must focus on one or both of these.
Reduced NOx emissions will also influence
concentrations of pollutants other than
ozone, including reduced formation of
secondary nitrate particles, acidic precipita-
tion, and gaseous NO2. A comprehensive
beneﬁt–cost analysis should account for the
health benefits associated with these pollu-
tants, along with visibility and other non-
health endpoints. On the other hand, it has
been argued that tropospheric ozone can be
protective, through reductions in UV-β radi-
ation and associated reductions in skin can-
cer and cataracts (113,114). It is unclear
whether any of these endpoints would mate-
rially influence control decisions for ozone
precursors, but any benefit–cost analysis of
ozone mitigation should include these ancil-
lary beneﬁts and risks. 
Conclusions
Our objective in this paper was to survey the
limited evidence used to estimate beneﬁts of
ozone mitigation and to discuss some of the
underlying uncertainties. We found biologi-
cally plausible evidence of mortality and respi-
ratory morbidity from ozone exposure, but the
limited number of studies and possible geo-
graphic variations in concentration–response
functions lead to uncertainties in specific
applications. Uncertainties regarding the
approach for valuation of premature death are
substantial, partly because past studies of will-
ingness to pay have not focused on the
populations most affected by ozone. We deter-
mined that the benefits of ozone reduction
may be greater than previously estimated
because of the possible independent effect of
ozone on premature mortality, but this con-
clusion is contingent on the economic value
placed on mortality. Future research should
focus on ozone-related mortality, both reﬁning
the monetary valuation and evaluating the evi-
dence in varied climates to conﬁrm hypothe-
sized exposure-related trends.
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